Skip to main content
Xiangxue Pharmaceutical Co., Ltd. logo

Xiangxue Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 300147 ISIN · CNE100000Y92 LEI · 3003000D8UMO4KQ95B57 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,287 across all filing types
Latest filing 2023-04-21 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300147

About Xiangxue Pharmaceutical Co., Ltd.

https://www.xphcn.com

Xiangxue Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and distribution of modern Traditional Chinese Medicine (TCM), chemical drugs, and biological products. The company is recognized for its focus on the modernization of TCM, utilizing advanced technology to standardize and enhance traditional formulas. Its flagship products include anti-viral oral liquids and Banlan'gen granules, which are widely used for respiratory health. Beyond traditional treatments, the company has expanded into high-tech biomedical fields, including precision medicine and adoptive cell therapy, specifically TCR-T cell technology for cancer treatment. Xiangxue operates a comprehensive value chain encompassing medicinal herb cultivation, pharmaceutical manufacturing, and healthcare services. By integrating digital technology with pharmaceutical expertise, the company aims to provide integrated health solutions and innovative therapies.

Recent filings

Filing Released Lang Actions
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Guangzhou Xiangxue Pharmaceutical Co., Ltd. regarding the approval of various reports and proposals related to the 2022 fiscal year, including the Supervisory Board Work Report, the 2022 Financial Final Accounts Report, the 2022 Audit Report and Financial Statements, the 2022 Annual Report and its summary, profit distribution plan, internal control self-evaluation report, and other related matters. The document states that these reports have been reviewed and approved by the Supervisory Board and will be submitted to the 2022 Annual General Meeting for further approval. The document itself does not contain the full reports but references that the detailed reports are disclosed elsewhere (e.g., on the Juchao Information Network). The document is relatively short (2710 characters) and serves as an official announcement of the Supervisory Board's resolutions rather than the full annual report or audit report itself. Therefore, according to the "Menu vs Meal" rule, this document is best classified as a Regulatory Filing (RNS) because it is an official regulatory announcement of meeting resolutions and approvals, not the full report.
2023-04-21 Chinese
内部控制鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制鉴证报告" (Internal Control Assurance Report) and includes a detailed internal control self-evaluation report for the fiscal year ending December 31, 2022. It is issued by a certified public accounting firm and addresses the effectiveness of internal controls related to financial reporting. The content includes management responsibilities, auditor responsibilities, internal control environment, risk assessment, control activities, information and communication, internal supervision, and internal control defect identification and remediation. It is a standalone audit-related report focusing on internal control effectiveness rather than a full annual report or interim financial statements. The document length is over 10,000 characters, indicating it is a full report, not just an announcement. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit-related report on internal controls and does not constitute a full annual report (10-K) or interim report (IR). FY 2022
2023-04-21 Chinese
2022年度财务决算报告
Annual Report Classification · 95% confidence The document is titled as a "2022年度财务决算报告" which translates to "2022 Annual Financial Settlement Report". It contains detailed financial data for the full fiscal year 2022, including revenue, profit, segment breakdowns, asset and liability changes, cash flow statements, and key financial ratios. The report is audited by a CPA firm with an unqualified opinion, indicating it is a formal financial report. The length is 3560 characters, which is relatively short but contains substantive financial data and analysis, not just an announcement or certification. Therefore, it is a full annual financial report rather than a brief announcement or certification. This matches the definition of an Annual Report (10-K). FY 2022
2023-04-21 Chinese
第九届董事会第八次会议决议公告
Capital/Financing Update Classification · 95% confidence The document is a formal announcement of a board meeting resolution regarding the approval of a loan restructuring proposal. It includes details about the meeting date, participants, voting results, and authorization for signing related legal documents. There is no detailed financial data, quarterly or annual financial statements, or comprehensive report content. The document is not a full financial report but an announcement of a board decision related to financing. Given the content focuses on financing activities (loan restructuring), the most appropriate classification is Capital/Financing Update (CAP). The document length is short and it is not merely announcing the publication of a report, so it is not RPA or RNS. Confidence is high due to clear meeting resolution and financing context.
2023-04-17 Chinese
关于申请借款重组的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's application for loan restructuring, detailing the loan amounts, guarantees, collateral, approval procedures, and the impact on the company. It includes information about board resolutions and independent directors' opinions related to the loan restructuring. The document is relatively short (2456 characters) and focuses on financing activities rather than presenting financial statements or detailed financial performance. There is no indication of it being a full financial report, audit report, or earnings release. The content fits the description of a Capital/Financing Update, as it provides updates on the company's financing activities and capital structure changes.
2023-04-17 Chinese
独立董事关于第九届董事会第八次会议相关事项的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent director's opinion on a borrowing restructuring and guarantee matter related to the company's board meeting. It references compliance with stock exchange listing rules and company articles but does not contain financial statements or detailed financial data. The content is related to board oversight and approval of financing activities but is not a full financing update or capital structure change announcement. It is a regulatory compliance opinion document related to board matters and financing but does not fit into categories like CAP or MANG fully. Given the short length (481 characters) and nature of the document, it is best classified as a Regulatory Filing (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2023-04-17 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.